[1] Wang Z, Ping F, Zhang Q, et al. Preliminary screening of mutations in the glucokinase gene of Chinese patients with gestational diabetes[J]. J Diabetes Invest, 2018, 9: 199-203. [2] 王志新,平凡,张茜,等. 中国妊娠期血糖异常人群葡萄糖激酶基因突变初步筛查[J]. 中华糖尿病杂志, 2014, 6: 397-401. [3] Osbak K, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia[J]. Hum Mutat, 2009, 30: 1512-1526. [4] Marotta D, Anand G, Anderson T, et al. Identification and characterization of the ATP-binding site in human pancreatic glucokinase[J]. Arch Biochem Biophys, 2005, 436: 23-31. [5] Marks S, Couch R. Identification of two new mutations in the glucokinase gene that result in maturity-onset diabetes of the young[J]. Diabetes Care, 2010, 33: e94. doi: 10.2337/dc10-0685. [6] Estalella I, Rica I, Perez De Nanclares G, et al. Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain[J]. Clin Endocrinol (Oxf), 2007, 67: 538. doi: 10.1111/j.1365-2265.2007.02921.x. [7] 王志新,于淼,郑佳,等. 四例中国青少年的成人起病型糖尿病2型家系的临床与分子遗传学研究[J]. 中华糖尿病杂志, 2014, 6: 21-26. [8] Wang Z, Diao C, Liu Y, et al. Identification and functional analysis of GCK gene mutations in 12 Chinese families with hyperglycemia[J]. J Diabetes Invest, 2019, 10: 963-971. [9] Thanabalasingham G, Owen K. Diagnosis and manage-ment of maturity onset diabetes of the young (MODY)[J]. BMJ, 2011, 343: d6044. doi: 10.1136/bmj.d6044. [10] Stride A, Vaxillaire M, Tuomi T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load[J]. Diabetologia, 2002, 45: 427-435. [11] Stoffel M, Bell K, Blackburn C, et al. Identification of glucokinase mutations in subjects with gestational diabetes mellitus[J]. Diabetes, 1993, 42: 937-940. [12] Ellard S, Bellanne-Chantelot C, Hattersley A. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young[J]. Diabetologia, 2008, 51: 546-553. [13] Steele A, Shields B, Wensley K, et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia[J]. JAMA, 2014, 311: 279-286. [14] Fendler W, Malachowska B, Baranowska-Jazwiecka A, et al. Population-based estimates for double diabetes amongst people with glucokinase monogenic diabetes, GCK-MODY[J]. Diabet Med, 2014, 31: 881-883. [15] Liu L, Liu Y, Ge X, et al. Insights into pathogenesis of five novel GCK mutations identified in Chinese MODY patients[J]. Metabolism, 2018, 89: 8-17. [16] Martin D, Bellanne-Chantelot C, Deschamps I, et al. Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2)[J]. Diabetes Care, 2008, 31: 1321-1323. [17] Spegel P, Ekholm E, Tuomi T, et al. Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2)[J]. Diabetes, 2013, 62: 653-661. |